These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33827962)

  • 1. Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
    Lambe J; Risher H; Filippatou AG; Murphy OC; Sotirchos ES; Ehrhardt H; Ogbuokiri E; Pellegrini N; Toliver B; Luciano NJ; Davis S; Fioravante N; Kwakyi O; Prince JL; Calabresi PA; Fitzgerald KC; Saidha S
    Neurology; 2021 May; 96(20):e2525-e2533. PubMed ID: 33827962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.
    Button J; Al-Louzi O; Lang A; Bhargava P; Newsome SD; Frohman T; Balcer LJ; Frohman EM; Prince J; Calabresi PA; Saidha S
    Neurology; 2017 Feb; 88(6):525-532. PubMed ID: 28077493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.
    Zivadinov R; Tavazzi E; Hagemeier J; Carl E; Hojnacki D; Kolb C; Weinstock-Guttman B
    CNS Drugs; 2018 Aug; 32(8):763-770. PubMed ID: 29767815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive Multiple Sclerosis Is Associated with Faster and Specific Retinal Layer Atrophy.
    Sotirchos ES; Gonzalez Caldito N; Filippatou A; Fitzgerald KC; Murphy OC; Lambe J; Nguyen J; Button J; Ogbuokiri E; Crainiceanu CM; Prince JL; Calabresi PA; Saidha S;
    Ann Neurol; 2020 Jun; 87(6):885-896. PubMed ID: 32285484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis.
    Behbehani R; Abu Al-Hassan A; Al-Salahat A; Sriraman D; Oakley JD; Alroughani R
    PLoS One; 2017; 12(2):e0172120. PubMed ID: 28192539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS.
    You Y; Barnett MH; Yiannikas C; Parratt JDE; Matthews JG; Graham SL; Klistorner A
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33597189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients.
    Chan JK; Hernandez Martínez de Lapiscina E; Taylor C; Nguyen AL; Alba-Arbalat S; Devonshire V; Sayao AL; Carruthers R; Costello F; Traboulsee A
    J Neuroophthalmol; 2020 Mar; 40(1):37-43. PubMed ID: 32045393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Serum Neurofilament Light Chain With Inner Retinal Layer Thinning in Multiple Sclerosis.
    Sotirchos ES; Vasileiou ES; Filippatou AG; Fitzgerald KC; Smith MD; Lord HN; Kalaitzidis G; Lambe J; Duval A; Prince JL; Mowry EM; Saidha S; Calabresi PA
    Neurology; 2022 Aug; 99(7):e688-e697. PubMed ID: 35618438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative diagnostic accuracy of ganglion cell-inner plexiform and retinal nerve fiber layer thickness measures by Cirrus and Spectralis optical coherence tomography in relapsing-remitting multiple sclerosis.
    González-López JJ; Rebolleda G; Leal M; Oblanca N; Muñoz-Negrete FJ; Costa-Frossard L; Alvarez-Cermeño JC
    Biomed Res Int; 2014; 2014():128517. PubMed ID: 25313352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choroid plexus volume as a marker of retinal atrophy in relapsing remitting multiple sclerosis.
    Raghib MF; Bao F; Elkhooly M; Bernitsas E
    J Neurol Sci; 2024 Feb; 457():122884. PubMed ID: 38237367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis.
    Krämer J; Balloff C; Weise M; Koska V; Uthmeier Y; Esderts I; Nguyen-Minh M; Zimmerhof M; Hartmann A; Dietrich M; Ingwersen J; Lee JI; Havla J; Kümpfel T; Kerschensteiner M; Häußler V; Heesen C; Stellmann JP; Zimmermann HG; Oertel FC; Ringelstein M; Brandt AU; Paul F; Aktas O; Hartung HP; Wiendl H; Meuth SG; Albrecht P
    Nat Commun; 2024 Jun; 15(1):5243. PubMed ID: 38897994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of retinal atrophy in multiple sclerosis: A longitudinal study using spectral domain optical coherence tomography with segmentation analysis.
    Behbehani R; Adnan H; Al-Hassan AA; Al-Salahat A; Alroughani R
    Mult Scler Relat Disord; 2018 Apr; 21():56-62. PubMed ID: 29459346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post Hoc Analyses of the SPRINT-MS Trial.
    Ehrhardt H; Lambe J; Moussa H; Vasileiou ES; Kalaitzidis G; Murphy OC; Filippatou AG; Pellegrini N; Douglas M; Davis S; Nagy N; Quiroga A; Hu C; Zambriczki Lee A; Duval A; Fitzgerald KC; Prince JL; Calabresi PA; Sotirchos ES; Bermel R; Saidha S
    Neurology; 2023 Sep; 101(10):e1014-e1024. PubMed ID: 37460235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of disease modifying therapy and retinal atrophy in relapsing-remitting multiple sclerosis.
    Kabanovski A; Zaslavsky K; Rotstein D; Margolin E
    J Neurol Sci; 2023 Mar; 446():120552. PubMed ID: 36774748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Racial differences in retinal neurodegeneration as a surrogate marker for cortical atrophy in multiple sclerosis.
    Lichtman-Mikol S; Razmjou S; Yarraguntla K; Bao F; Santiago-Martinez C; Seraji-Bozorgzad N; Bernitsas E
    Mult Scler Relat Disord; 2019 Jun; 31():141-147. PubMed ID: 30991300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyper-reflective foci changes in RRMS under natalizumab therapy.
    Puthenparampil M; Basili E; Ponzano M; Mauceri VA; Miscioscia A; Pilotto E; Perini P; Rinaldi F; Bovis F; Gallo P
    Front Immunol; 2024; 15():1421755. PubMed ID: 39076978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Retinal Layer Thickness and Disability Worsening in Relapsing-Remitting and Progressive Multiple Sclerosis.
    Cellerino M; Priano L; Bruschi N; Boffa G; Petracca M; Novi G; Lapucci C; Sbragia E; Uccelli A; Inglese M
    J Neuroophthalmol; 2021 Sep; 41(3):329-334. PubMed ID: 33399416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Retinal Architecture, Intrathecal Immunity, and Clinical Course in Multiple Sclerosis.
    Knier B; Leppenetier G; Wetzlmair C; Aly L; Hoshi MM; Pernpeintner V; Biberacher V; Berthele A; Mühlau M; Zimmer C; Hemmer B; Korn T
    JAMA Neurol; 2017 Jul; 74(7):847-856. PubMed ID: 28460032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.